Shots:

• The P-III PRIME2 trial evaluates Dupixent vs PBO with/out topical treatments in 160 adults with PN inadequately controlled with topical prescription therapies
• The trial met its 1EPs and all key 2EPs i.e.- patients experienced a reduction in itch from baseline (37% vs 22%) @12wks.; reduction in itch from baseline (58% vs 20%) & patients achieved clear or almost clear skin (45% vs 16%) @24wks.- greater improvements in measures of health-related QoL- skin pain & symptoms of anxiety & depression
• Additionally- safety results were consistent with the known safety profile of Dupixent in its approved indications- patients discontinued the treatment (3% & 30%) before 24wks.

 ­ | Ref: PR Newswire | Image: The Print